Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan Approves Janssen’s COVID Jab, Sanofi’s Sutimlimab, Olumiant’s Alopecia Use and More
Japan health ministry approved a batch of new medicines and indications on June 20 including Janssen Pharmaceutical’s COVID-19 vaccine Jcovden and Sanofi’s anti-C1s monoclonal antibody Enjaymo (sutimlimab). Jcovden, a recombinant vector vaccine, has now become the fifth jab approved in…
To read the full story
Related Article
- Chuikyo OKs Lagevrio, Voxzogo, Enjaymo, and More for August Listing, BioMarin Med with Biggest Peak Sales Outlook
August 10, 2022
- MHLW Panel Endorses Sanofi’s Sutimlimab as Japan’s First CAD Therapy
June 3, 2022
- Japan Panel OKs Taiho’s GIST Med, ViiV/Janssen’s HIV Combo and More for Approval
May 31, 2022
- Janssen’s COVID-19 Vaccine in Line for Japan Approval, No Supply Deal Signed
May 31, 2022
REGULATORY
- MHLW Revises Biological Raw Material Rules, Clarifies Donor Testing Flexibility
April 2, 2026
- Japan Officially Eases Trial Recruitment Rules; Industry Welcomes Move
April 1, 2026
- MHLW Updates Q&A on Use of Registry Data in Drug Applications
April 1, 2026
- Japan Panel Designates Two Ebola Therapies for Early Approval Pathway
April 1, 2026
- MHLW, METI Launch Joint Task Force to Safeguard Medical Supply Chains
April 1, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…